On May 28, 2026 NETRIS Pharma, a clinical-stage oncology company targeting the netrin-1 / epithelial-to-mesenchymal transition (EMT) axis, reported that it has secured €7.25 million in funding under the European Union’s Horizon Europe programme to conduct a Phase 2b randomized clinical trial of NP137 in head and neck squamous cell carcinoma (HNSCC). The trial will be led by Principal Investigator Dr. Jérôme Fayette, MD, PhD, a medical oncologist at Centre Léon Bérard (Lyon, France), and conducted in partnership with GORTEC (Groupe Oncologie Radiothérapie Tête Et Cou), the leading French cooperative oncology group in HNSCC led by Professor Jean Bourhis and TTCC group, the Spanish group for the treatment of head and neck tumors, chaired by Dr. Ricard Mesia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

« Head and neck squamous cell carcinoma remains a disease with significant unmet need, particularly with a large portion of patients relapsing under immunotherapy. The scientific rationale for targeting netrin-1 in HNSCC to alleviate resistance to immunotherapy and thus extend the survival of patients is compelling,and the clinical outcomes from the Phase2 ImmunoNET study confirms the potential of NP137 to deliver meaningful clinical benefit for our patients » said Dr. Jérôme Fayette, MD, PhD, Principal Investigator and Medical Oncologist at Centre Léon Bérard.

Patrick Mehlen, PhD, Chief Executive Officer of NETRIS Pharma, said: « We are delighted to receive this Horizon Europe grant, which is a further validation of both our scientific approach and our development strategy in head and neck cancer. NP137 is the only clinical-stage anti-netrin1 therapy, and HNSCC is a key indications given the resistance to current treatment. Conducting this Phase 2b study in partnership with GORTEC, the most experienced cooperative group in this field, and under the leadership of Dr. Fayette, provides the ideal framework to generate the high-quality clinical evidence needed to advance NP137 toward regulatory discussions. This funding reinforces our commitment to bringing truly differentiated therapies to patients with limited options ».

« GORTEC is proud to partner with NETRIS Pharma on this innovative Phase 2b programme. Head and neck cancer is a field where new mechanistic approaches are urgently needed. The netrin-1 / EMT axis represents a clinically actionable target, and we look forward to generating robust data in the context of this well-designed Horizon Europe-funded trial » said Professor Jean Bourhis, Chief Executive Officer and Chief Medical Officer of GORTEC.

The Horizon Europe programme is the European Union’s key funding mechanism for research and innovation. « Following the positive outcome of the immunonet study, this funding reflects the high value of NP137 in oncology », said Christophe Guichard, Chief Financial Officer of NETRIS Pharma. The funding will support the design, conduct and analysis of the Phase 2b randomized trial in HNSCC, building on the clinical evidence supporting the role of netrin-1 in driving treatment resistance in this indication. The project will be conducted through a consortium led by NETRIS Pharma with GORTEC, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello – TTCC and Université Libre de Bruxelles.

About the Phase 2b HNSCC Trial

The Phase 2b trial is a randomized, multi-center study evaluating NP137 in patients with head and neck squamous cell carcinoma. The study will be conducted across multiple centers in France and Spain under the sponsorship of GORTEC, with Dr. Jérôme Fayette of Centre Léon Bérard serving as Principal Investigator. The trial design will incorporate translational endpoints aimed at further characterizing the role of netrin-1 and its receptors as predictive biomarkers of response to NP137, consistent with NETRIS Pharma’s precision oncology development strategy.

Full details of the trial design, including patient population, primary and secondary endpoints, and treatment schedule, will be disclosed at the time of trial initiation.

About Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and neck squamous cell carcinoma (HNSCC) encompasses cancers of the oral cavity, pharynx, larynx, and other structures of the upper aerodigestive tract. It represents the sixth most common cancer worldwide, with approximately 900,000 new cases and 450,000 deaths annually. Despite advances in surgery, radiotherapy, and systemic therapy including checkpoint inhibitor immunotherapy, outcomes for patients with recurrent and/or metastatic HNSCC remain poor, with median overall survival of approximately 14–15 months with current standard-of-care regimens.

NETRIS Pharma has established a scientific rationale for netrin-1 blockade in HNSCC based on the role of netrin-1 in driving epithelial-to-mesenchymal transition (EMT) and acquired resistance to treatment, mechanisms that are highly relevant in this tumor type. NP137 is currently in clinical development in HNSCC as part of NETRIS Pharma’s broader multi-indication development strategy.

About GORTEC

GORTEC (Groupe Oncologie Radiothérapie Tête Et Cou) is the leading French cooperative oncology group dedicated to the clinical development of innovative treatments for head and neck cancers. GORTEC has conducted numerous landmark clinical trials in HNSCC and is widely recognized as one of the most prolific and scientifically rigorous cooperative groups in this field in Europe. The group is led by Professor Jean Bourhis, a world-leading expert in head and neck oncology and radiation oncology.

(Press release, Netris Pharma, MAY 28, 2026, View Source [SID1234666150])

On May 28, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 10:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

(Press release, Merck & Co, MAY 28, 2026, View Source [SID1234666149])

On May 28, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, reported the closing of its previously announced marketed public offering of units (the "Units") of the Company at a price to the public of CDN$0.50 per Unit (the "Offering"), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds the Company may receive from the exercise of the underlying warrants. Pursuant to the Offering, the Company issued a total of 8,880,000 Units. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company (a "Warrant Share") at an exercise price of $0.65 per Warrant Share until the date that is three years following the initial closing date of the Offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Offering was made pursuant to an agency agreement (the "Agency Agreement") entered into between Bloom Burton Securities Inc., as sole agent (the "Agent"), and the Company dated May 21, 2026. An aggregate of 450,100 compensation warrants of the Company (each, a "Broker Warrant") were issued by the Company in connection with the Agency Agreement, each Broker Warrant entitling the holder to acquire one common share of the Company at an exercise price of $0.50 per share until the date that is two years following the initial closing date of the Offering.

The Offering was made pursuant to a prospectus supplement (the "Prospectus Supplement") dated May 21, 2026 to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the "Base Shelf Prospectus") filed in the Provinces of British Columbia, Alberta and Ontario. The Units may also be offered in certain other jurisdictions outside of Canada, provided that a placement therein does not give rise to any prospectus, registration or continuous disclosure obligations on the part of the Company.

The Base Shelf Prospectus, the Agency Agreement and the Prospectus Supplement are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

The securities of the Company described above have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any U.S. state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the "United States" or "U.S. Persons" (as such terms are defined in Regulation S under the 1933 Act) except pursuant to an effective registration statement under the 1933 Act and applicable U.S. state securities laws or an available exemption from the registration requirements of the 1933 Act and applicable U.S. state securities laws.

In addition to the above Offering and as announced previously, the Company has entered into a separate structured financing of CDN$8.0 million with Sorbie Bornholm LP and Sorbie Investments LLP ("Sorbie").

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Medicenna Therapeutics, MAY 28, 2026, View Source [SID1234666148])

On May 28, 2026 Massive Bio, a global leader in AI-enabled oncology trial access and precision oncology navigation, reported that it will unveil the next phase of Reticulum Nexus, its trusted multi-agent oncology intelligence ecosystem, during the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reticulum Nexus is designed to address one of oncology’s most persistent failures: the gap between the rapid pace of cancer innovation and the ability of patients, physicians, trial sites, and sponsors to coordinate action in real time. The platform connects patient engagement, medical record ingestion, eligibility interpretation, clinical trial pre-screening, physician referral orchestration, biomarker intelligence, site activation, patient navigation, and longitudinal follow-up into a single AI-enabled operating layer.

"Cancer patients are not lost because science is absent. They are lost because the system around them is fragmented," said Selin Kurnaz, PhD, Co-Founder and CEO of Massive Bio. "Reticulum Nexus was built to make oncology access coordinated, measurable, trusted, and fast. We are moving from point solutions to infrastructure."

The ASCO (Free ASCO Whitepaper) announcement builds on several recent Massive Bio milestones: the company’s collaboration with OpenAI to transform complex trial criteria into structured, machine-readable parameters for AI-enabled pre-screening; its collaboration with the American Cancer Society’s ACS ACTS program to expand equitable clinical trial access nationally; its DiMe Seal and CMS Medicare App Library listing; and the publication of peer-reviewed prospective evidence demonstrating AI-driven trial matching at scale.

From Trial Matching to Oncology Orchestration

For years, cancer trial access has been treated as a search problem: find a patient, find a protocol, compare eligibility, and generate a match. But in real-world oncology, matching is only the beginning. Patients need records collected, eligibility clarified, biomarkers interpreted, physicians engaged, referrals routed, sites activated, social barriers addressed, and follow-up maintained.

Reticulum Nexus is designed to orchestrate those steps through coordinated AI agents and human-in-the-loop workflows. The ecosystem brings together Patient Connect, the patient-facing digital front door for record upload, trial matching, and care coordination; TrialRelay, the physician-facing referral orchestration platform powered by the TrialRouter AI agent; NexusPulse, the real-time AI signal engine that turns consented real-world data into prioritized next-best actions; DrArturo AI, the clinician-facing oncology intelligence agent; Phoebe AI, the patient-facing navigation intelligence agent; and Sentinel Agents, a family of monitoring agents designed to detect critical clinical, operational, equity, safety, and biomarker signals earlier in the patient journey.

"Reticulum Nexus is not a chatbot and it is not a dashboard," said Arturo Loaiza-Bonilla, MD, MSEd, FACP, Co-Founder and Chief Medical AI Officer of Massive Bio. "It is a multi-agent oncology operating system. It understands context, detects urgency, routes action, supports clinicians, engages patients, and keeps the workflow moving until the loop is closed."

Built on Trust, Evidence, and National Reach

The next phase of Reticulum Nexus is being launched at a time when oncology AI is moving from experimentation to operational deployment. Massive Bio’s April 2026 collaboration with OpenAI is focused on AI-powered protocol parameterization and pre-screening, allowing complex clinical trial criteria from sponsors and public registries to be transformed into structured, machine-readable parameters.

The company’s platform has earned the DiMe Seal and is listed in the CMS Medicare App Library, a trusted centralized directory where Medicare beneficiaries can discover vetted digital health options that have undergone review for security, privacy, clinical evidence, usability, and equity. The Medicare.gov App Library lists Massive Bio Patient Navigator as helping cancer patients find and access matched clinical trials and personalized care options based on diagnosis, genomic profile, and treatment history.

Through the American Cancer Society’s ACS ACTS program, ACS is working with Massive Bio for AI-driven clinical trial matching services to bring patients tailored options and support resources, including education, cancer information specialist support, transportation, lodging, and other needs-based assistance.

Massive Bio’s recent peer-reviewed prospective study reported that its neuro-symbolic, multi-agent AI platform matched cancer patients to clinical trials four times faster than conventional methods, across 3,804 patients, more than 157,000 clinical document pages, and more than 17,000 oncologist-confirmed trial matches.

"Trust is the multiplier," said Selin Kurnaz. "AI in oncology cannot scale on novelty alone. It must be evidence-based, privacy-aware, interoperable, auditable, and grounded in real patient workflows. That is why Reticulum Nexus is being built not just as technology, but as infrastructure."

ASCO Demonstration: The Closed-Loop Oncology Journey

At ASCO (Free ASCO Whitepaper) 2026, Massive Bio will demonstrate how Reticulum Nexus can coordinate a patient journey from first engagement to trial activation. A patient may enter through Patient Connect, provide consent, and upload records. DrArturo AI can help structure the clinical context. OpenAI-enabled parameterization can support protocol interpretation and pre-screening. NexusPulse can detect urgency, trial opportunity, biomarker gaps, or access friction. Sentinel Agents can monitor clinical, referral, safety, and equity signals. TrialRelay can route physician-to-physician handoffs. Phoebe AI can support patient education, navigation, and follow-up. ACS ACTS resources can help address support needs.

The result is a coordinated, human-in-the-loop infrastructure designed to help patients move from possibility to action.

"Massive Bio is turning clinical trial access from a search problem into a real-time orchestration problem," said Dr. Loaiza-Bonilla. "The science is there. The patients are there. What has been missing is the operating system that connects them. That is Reticulum Nexus."

(Press release, Massive Bio, MAY 28, 2026, View Source [SID1234666147])

On May 28, 2026 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that the Company’s senior management team will participate at the 2026 Jefferies Global Healthcare Conference in a fireside chat on Thursday, June 4, 2026 at 8:10 a.m. ET in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the Company’s website, View Source, and will be available for replay following the event.

(Press release, Karyopharm, MAY 28, 2026, View Source [SID1234666146])